The CDE recently accepted Innovent Biologics and GenFleet Therapeutics' joint NDA for GF-105, prioritizing its review for advanced NSCLC patients with the KRAS G12C mutation after first-line therapy.

The latest clinical findings of Igrelimogene litadenorepvec were unveiled at the 2023 ESMO_IO, demonstrating its potential benefit and setting the stage for subsequent investigations.

Innovent declared the successful completion of the initial stage 3 clinical evaluation for Mazdutide among overweight and obese adults in China.

Run in period and washout period are two commonly used concepts in clinical trials.

The EU Commission has approved Eylea™ 8 mg, an 8 mg aflibercept (114.3 mg/ml) injectable, for treating neovascular age-related macular degeneration and diabetic macular edema-related vision loss.

Abbisko Therapeutics entered into an exclusive license deal with Merck, Germany, for its CSF-1R inhibitor, Pimicotinib (ABSK021).

Bayer announced positive early results from Phase III OASIS 1 and 2 trials, where the experimental drug elinzanetant outperformed placebo.

To eliminate variability in lab results due to different instruments and technicians across centers, all blood or urine samples from the multicenter trial are analyzed and reported by a single lab.

Curevo Vaccine has reported its second-phase study for Amezosvatein, This advanced shingles immunization demonstrates effectiveness against Shingrix in direct comparison.

On Jan 2, 2024, MediLink Therapeutics and Roche entered a global deal to develop YL211, an ADC targeting c-MET for solid tumors.

OKYO Pharma Corporation has disclosed that OK-101 has met its primary efficacy benchmarks in Phase 2 human trials, demonstrating statistical relevance in treating dry eye condition.

Laboratory tests are often part of the safety assessment in clinical trials of unlisted drugs, and blood samples are used for clinical biochemistry and blood.